Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetomilast in Active Crohn's Disease
NCT00317369Phase 2Terminated
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- May 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tetomilast in Crohn's disease (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Clinical Improvement Rate at 8 weeks. Started May 2006; status: terminated.
02
Drugs
tetomilast
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00317369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317369.